The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Dynastat     N-[4-(5-methyl-3-phenyl-1,2- oxazol-4...

Synonyms: Parecoxib, parecoxibum, SureCN9529, CHEMBL1206690, CHEBI:73038, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Dynastat

 

Psychiatry related information on Dynastat

  • In eight healthy subjects, a freeze lesion was induced and mechanical pain thresholds (MPT) were tested for 5h following administration of the non-selective COX inhibitor diclofenac (75mg), the COX-2-selective inhibitor parecoxib (40mg) or placebo in a randomized, double-blind cross-over study [6].
 

High impact information on Dynastat

 

Chemical compound and disease context of Dynastat

 

Biological context of Dynastat

 

Anatomical context of Dynastat

 

Associations of Dynastat with other chemical compounds

 

Gene context of Dynastat

 

Analytical, diagnostic and therapeutic context of Dynastat

  • Patients were allocated randomly to groups to receive the non-selective COX-inhibitor, acetylsalicylate-lysin (500 mg intravenously), or the selective COX-2 inhibitor, parecoxib, an injectable prodrug of valdecoxib (20 mg intravenously) [4].
  • BACKGROUND: The analgesic efficacy and side effect profile of intravenous parecoxib, a novel cyclooxygenase type-2 (COX-2) inhibitor, was assessed in a double-blinded, placebo-controlled study involving patients undergoing major gynecologic surgical procedures [14].
  • In this multicenter, double-blinded, randomized, placebo-controlled study we evaluated the analgesic and opioid-sparing efficacy of a preoperative dose of i.v. parecoxib followed by oral valdecoxib in treating pain associated with elective laparoscopic cholecystectomy [26].
  • Patients were allocated at a ratio of 2:1 to parecoxib/valdecoxib or standard care (control) groups, respectively [27].
  • OBJECTIVE: We aimed to investigate the effects of the cyclooxygenases-2 (COX-2) inhibitor parecoxib on meningeal plasma protein extravasation (PPE) and on c-fos expression in the nucleus trigeminalis caudalis in an animal model of trigeminovascular activation [18].

References

  1. Cyclooxygenase-2 is a target of KRASD12, which facilitates the outgrowth of murine C26 colorectal liver metastases. Smakman, N., Kranenburg, O., Vogten, J.M., Bloemendaal, A.L., van Diest, P., Borel Rinkes, I.H. Clin. Cancer Res. (2005) [Pubmed]
  2. Parecoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs. Viola, M., Quaratino, D., Volpetti, S., Gaeta, F., Romano, A. J. Allergy Clin. Immunol. (2006) [Pubmed]
  3. The cyclooxygenase isozyme inhibitors parecoxib and paracetamol reduce central hyperalgesia in humans. Koppert, W., Wehrfritz, A., Körber, N., Sittl, R., Albrecht, S., Schüttler, J., Schmelz, M. Pain (2004) [Pubmed]
  4. Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension. Bulut, D., Liaghat, S., Hanefeld, C., Koll, R., Miebach, T., Mügge, A. J. Hypertens. (2003) [Pubmed]
  5. Parecoxib (parecoxib sodium). Cheer, S.M., Goa, K.L. Drugs (2001) [Pubmed]
  6. Pharmacological and histopathological characterization of a hyperalgesia model induced by freeze lesion. Schmidtko, A., Burian, M., Altis, K., Hardt, K., Angioni, C., Schmidt, R., Podda, M., Geisslinger, G. Pain (2007) [Pubmed]
  7. COX-2 inhibition prevents downregulation of key renal water and sodium transport proteins in response to bilateral ureteral obstruction. Nørregaard, R., Jensen, B.L., Li, C., Wang, W., Knepper, M.A., Nielsen, S., Frøkiaer, J. Am. J. Physiol. Renal Physiol. (2005) [Pubmed]
  8. The second generation of COX-2 inhibitors: what advantages do the newest offer? Stichtenoth, D.O., Frölich, J.C. Drugs (2003) [Pubmed]
  9. Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery. Nussmeier, N.A., Whelton, A.A., Brown, M.T., Joshi, G.P., Langford, R.M., Singla, N.K., Boye, M.E., Verburg, K.M. Anesthesiology (2006) [Pubmed]
  10. Postoperative modulation of central nervous system prostaglandin E2 by cyclooxygenase inhibitors after vascular surgery. Reuben, S.S., Buvanendran, A., Kroin, J.S., Steinberg, R.B. Anesthesiology (2006) [Pubmed]
  11. A randomized, double-blind comparison between parecoxib sodium and propacetamol for parenteral postoperative analgesia after inguinal hernia repair in adult patients. Beaussier, M., Weickmans, H., Paugam, C., Lavazais, S., Baechle, J.P., Goater, P., Buffin, A., Loriferne, J.F., Perier, J.F., Didelot, J.P., Mosbah, A., Said, R., Lienhart, A. Anesth. Analg. (2005) [Pubmed]
  12. Effects of oral pregabalin and aprepitant on pain and central sensitization in the electrical hyperalgesia model in human volunteers. Chizh, B.A., Göhring, M., Tröster, A., Quartey, G.K., Schmelz, M., Koppert, W. British journal of anaesthesia (2007) [Pubmed]
  13. Effects of parecoxib, a parenteral COX-2-specific inhibitor, on the pharmacokinetics and pharmacodynamics of propofol. Ibrahim, A., Park, S., Feldman, J., Karim, A., Kharasch, E.D. Anesthesiology (2002) [Pubmed]
  14. Effect of parecoxib, a novel intravenous cyclooxygenase type-2 inhibitor, on the postoperative opioid requirement and quality of pain control. Tang, J., Li, S., White, P.F., Chen, X., Wender, R.H., Quon, R., Sloninsky, A., Naruse, R., Kariger, R., Webb, T., Norel, E. Anesthesiology (2002) [Pubmed]
  15. Influence on platelet aggregation of i.v. parecoxib and acetaminophen in healthy volunteers. Munsterhjelm, E., Niemi, T.T., Ylikorkala, O., Neuvonen, P.J., Rosenberg, P.H. British journal of anaesthesia. (2006) [Pubmed]
  16. Parecoxib sodium, an injectable COX-2-specific inhibitor, does not affect unfractionated heparin-regulated blood coagulation parameters. Noveck, R.J., Hubbard, R.C. Journal of clinical pharmacology. (2004) [Pubmed]
  17. Combination therapy using the cyclooxygenase-2 inhibitor Parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin. Koppe, M.J., Oyen, W.J., Bleichrodt, R.P., Hendriks, T., Verhofstad, A.A., Goldenberg, D.M., Boerman, O.C. Cancer Immunol. Immunother. (2006) [Pubmed]
  18. Effects of parecoxib on plasma protein extravasation and c-fos expression in the rat. Schuh-Hofer, S., Tayefeh, M., Reuter, U., Dirnagl, U., Arnold, G. Headache. (2006) [Pubmed]
  19. Parecoxib impairs early tendon repair but improves later remodeling. Virchenko, O., Skoglund, B., Aspenberg, P. The American journal of sports medicine. (2004) [Pubmed]
  20. Pharmacological profile of parecoxib: a novel, potent injectable selective cyclooxygenase-2 inhibitor. Padi, S.S., Jain, N.K., Singh, S., Kulkarni, S.K. Eur. J. Pharmacol. (2004) [Pubmed]
  21. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Ibrahim, A.E., Feldman, J., Karim, A., Kharasch, E.D. Anesthesiology (2003) [Pubmed]
  22. The cardioprotective effects of preconditioning with endotoxin, but not ischemia, are abolished by a peroxisome proliferator-activated receptor-gamma antagonist. Sivarajah, A., McDonald, M.C., Thiemermann, C. J. Pharmacol. Exp. Ther. (2005) [Pubmed]
  23. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. Gerstenfeld, L.C., Thiede, M., Seibert, K., Mielke, C., Phippard, D., Svagr, B., Cullinane, D., Einhorn, T.A. J. Orthop. Res. (2003) [Pubmed]
  24. Clinical pharmacology of selective COX-2 inhibitors. Capone, M.L., Tacconelli, S., Sciulli, M.G., Patrignani, P. International journal of immunopathology and pharmacology. (2003) [Pubmed]
  25. The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam. Ibrahim, A., Karim, A., Feldman, J., Kharasch, E. Anesth. Analg. (2002) [Pubmed]
  26. Effective treatment of laparoscopic cholecystectomy pain with intravenous followed by oral COX-2 specific inhibitor. Joshi, G.P., Viscusi, E.R., Gan, T.J., Minkowitz, H., Cippolle, M., Schuller, R., Cheung, R.Y., Fort, J.G. Anesth. Analg. (2004) [Pubmed]
  27. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. Ott, E., Nussmeier, N.A., Duke, P.C., Feneck, R.O., Alston, R.P., Snabes, M.C., Hubbard, R.C., Hsu, P.H., Saidman, L.J., Mangano, D.T. J. Thorac. Cardiovasc. Surg. (2003) [Pubmed]
 
WikiGenes - Universities